General Objective:
The general objective of this complimentary Joint Action on Health Technology Assessment (JA2) is to strengthen the practical application of tools and approaches to cross-border HTA collaboration. The JA2 aims at bringing collaboration to a higher level resulting in better understanding for the Commission and Member States (MS) of the ways to establish a sustainable structure for HTA in the EU.
Specifically, the JA2 will develop a general strategy, principles and an implementation proposal for a sustainable European HTA collaboration according to the requirements of Article 15 of the Directive for cross-border healthcare.



This Joint Action aims to enable coordinated pharmacovigilance operations in the EU network, making best use of worksharing and resources. A key aim is to help lower-resourced Member States develop skills and capacity in pharmacovigilance network to benefit citizens in their territory and the whole network. The Joint Action will help ensure a consistent approach across all member states for collecting information on adverse drug reactions; identifying safety issues; communicating risk and assessing risk minimisation measures all within the operation a standardised quality management system. This will benefit medicines safety monitoring and communications outputs and thereby help to safeguard public health.




The focus of the conference will be on the discrepancy between the antibiotic
resistance threat and the lack of new drugs foreseen in the pharmaceutical sector. The aim is to explore ways
of creating incentives for the development of new drugs. Such incentives could be changes in the regulatory
mechanisms, innovative financial instruments or other innovative mechanism.
